BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Merck's stock is suddenly soaring, but is the struggling healthcare giant a buy? Merck shares began peeling back in early ...

Merck Foundation Chairman & Chief Executive Officer (CEO) and the First Lady of Zimbabwe Celebrate 7 Years of Long-Term ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency’s ...

Merck (MRK) ended the recent trading session at $99.01, demonstrating a +1.42% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.21%. On the other hand, ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...